Explore

John Theurer Cancer Center Showcases Innovative Cancer Research at ASCO Annual Meeting

John Theurer Cancer Center Showcases Innovative Cancer Research at ASCO Annual Meeting

The John Theurer Cancer Center at Hackensack University Medical Center is presenting its latest cancer research at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. The center, part of the Lombardi Comprehensive Cancer Center at Georgetown University, is highlighting advancements in cellular therapy, immunotherapy, and treatments for blood cancers. Dr. Andre Goy, chair and vice president of oncology at the center, emphasized the importance of translating research into standard care, particularly for patients unresponsive to existing treatments. The center's research focuses on hematologic malignancies, solid tumors, and melanoma, aiming to improve patient outcomes across the Hackensack Meridian Health network.

Hologic's Breast Cancer Index Test Influences Endocrine Therapy Decisions for Breast Cancer Patients

Hologic's Breast Cancer Index Test Influences Endocrine Therapy Decisions for Breast Cancer Patients

Hologic, Inc. and its subsidiary, Biotheranostics, Inc., have announced new data demonstrating the impact of the Breast Cancer Index (BCI) Test on extended endocrine therapy decisions for patients with early-stage, hormone receptor-positive breast cancer. The BCI Test, recognized by the National Comprehensive Cancer Network and the American Society of Clinical Oncology, is the only genomic assay that predicts the likelihood of benefiting from extended endocrine therapy beyond five years. Recent analysis from the BCI Registry Study shows that physician recommendations for extended endocrine therapy increased by over 30% for patients identified by the BCI Test as likely to benefit, while recommendations decreased by nearly 40% for those unlikely to benefit. These findings will be presented at the 2026 ASCO Annual Meeting.

Stallergenes Greer Foundation Awards €100,000 to Innovators in Allergy Research

Stallergenes Greer Foundation Awards €100,000 to Innovators in Allergy Research

The Stallergenes Greer Foundation has announced the recipients of its 2025 Science Awards for Allergy, recognizing significant contributions to allergy research and patient engagement. The awards, totaling €100,000, were distributed among four researchers who excelled in two categories: Innovation in Treatment and Patient Commitment. The recipients include Assoc. Professor Alexander Eggel from the University of Bern, Dr. Janice A. Layhadi from Imperial College London, Dr. Laurent Reber from Inserm, and Dr. Pablo Rodríguez del Río from Hospital Infantil Universitario Niño Jesús. Their research spans from improving diagnostic and therapeutic options for allergic patients to developing allergen-specific mRNA vaccines and understanding patient perspectives in food immunotherapy.

Society of Hematologic Oncology Launches Registration for MDS/AML Program Ahead of SOHO 2026

Society of Hematologic Oncology Launches Registration for MDS/AML Program Ahead of SOHO 2026

The Society of Hematologic Oncology (SOHO) has opened registration for a case-based interactive session focused on myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The session, titled 'Practical Strategies for Optimizing Outcomes in MDS and AML,' will be held on September 8, 2026, in Houston, Texas, at the George R. Brown Convention Center. This event will precede the Fourteenth Annual Meeting of SOHO, scheduled for September 9-12, 2026. The session aims to provide clinicians with practical strategies and expert insights to integrate the latest advances in MDS and AML care into everyday clinical practice. Chaired by Dr. Guillermo Garcia-Manero from the University of Texas MD Anderson Cancer Center, the session will feature case-based discussions, live polling, and multidisciplinary perspectives. Notable speakers include Prof. Charles Craddock, Dr. Naval Daver, and Dr. Courtney D. DiNardo, among others.

FDA Extends Review of AstraZeneca's Breast Cancer Drug Camizestrant

FDA Extends Review of AstraZeneca's Breast Cancer Drug Camizestrant

The FDA has extended its review of AstraZeneca's camizestrant, an oral selective estrogen receptor degrader (SERD), for the treatment of HR-positive, HER2-negative breast cancer with ESR1 mutations. This decision follows a previous advisory committee vote against the drug, citing insufficient evidence of clinical benefit. AstraZeneca has provided additional data, including analyses of circulating tumor DNA, to support its application. The extension allows the FDA to thoroughly evaluate these new findings, which could potentially strengthen the case for camizestrant's approval.

Combat Medical's HIVEC HEAT Trial Highlights Potential for Bladder Cancer Treatment

Combat Medical's HIVEC HEAT Trial Highlights Potential for Bladder Cancer Treatment

Combat Medical has announced an update on its HIVEC HEAT trial at the American Urological Association Annual Meeting. The trial is a phase 3 study investigating the use of hyperthermic chemotherapy for bladder-sparing treatment in patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive to Bacillus Calmette-Guérin (BCG) therapy. The study, conducted across 25 sites in the UK, aims to support FDA registration. The trial uses Combat's bladder recirculation system to deliver chemotherapy at controlled temperatures, potentially increasing anti-tumor activity while preserving the bladder. The trial has shown promising results, with up to 83% disease-free survival after one year and a bladder preservation rate of nearly 80% after two years.

Vitamin D Analog Shows Potential in Enhancing Pancreatic Cancer Treatment

Vitamin D Analog Shows Potential in Enhancing Pancreatic Cancer Treatment

A clinical trial led by Dana-Farber Cancer Institute researchers has explored the use of paricalcitol, a vitamin D analog, in combination with standard chemotherapy for treating metastatic pancreatic cancer. The study, published in Nature Cancer, found that paricalcitol helps reshape the tumor microenvironment, making the cancer more susceptible to treatment. Patients receiving paricalcitol showed improved chemotherapy responses and increased progression-free survival. The trial also noted that patients with high vitamin D receptor expression had the longest overall survival. This approach leverages the body's natural systems to reduce fibrotic and inflammatory responses, potentially overcoming therapeutic resistance in pancreatic cancer.

Caris Life Sciences Launches Campaign Highlighting Genomic Testing Impact on Patient Care

Caris Life Sciences Launches Campaign Highlighting Genomic Testing Impact on Patient Care

Caris Life Sciences Launches Campaign Highlighting Genomic Testing Impact on Patient Care

UMass Chan Receives $1.6M Grant for Safer Gene Therapy Research

UMass Chan Receives $1.6M Grant for Safer Gene Therapy Research

UMass Chan Medical School has been awarded a $1.6 million federal grant from the National Institute of General Medical Sciences to enhance the safety of gene therapy delivery methods. The grant supports research led by Phillip Tai, an assistant professor of genetic and cellular medicine, focusing on adeno-associated viral vectors, a common tool in gene therapy. The research aims to improve the safety of these vectors, which are used to deliver genetic material into patients' cells. While gene therapy is generally safe, there are concerns about the potential for vectors to insert genetic material into DNA in ways that could contribute to cancer. Tai's team will use advanced DNA sequencing to study vector interactions with cells and explore redesigns to mitigate risks.

Caris Life Sciences to Present 32 Studies at ASCO 2026 Highlighting Advances in Precision Oncology

Caris Life Sciences to Present 32 Studies at ASCO 2026 Highlighting Advances in Precision Oncology

Caris Life Sciences, a leader in precision medicine, announced its participation in the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The company, along with its Precision Oncology Alliance and over 60 collaborating institutions, will present 32 studies. These studies cover a range of topics including breast, colorectal, lung, endometrial, and renal cell carcinoma, as well as pan-cancer analyses. The research focuses on multi-omic biomarker investigations and real-world data to enhance understanding of tumor biology and inform precision oncology approaches. Notable studies include those examining genetic ancestry's influence on melanoma and ESR1 amplification in breast cancer. The presentations aim to showcase the importance of comprehensive molecular profiling in advancing precision oncology.

Scientists Enhance Natural Killer Cells to Combat Aggressive Cancers

Scientists Enhance Natural Killer Cells to Combat Aggressive Cancers

Researchers at McGill University's Rosalind & Morris Goodman Cancer Institute have developed a new method to enhance the cancer-fighting abilities of natural killer (NK) cells. This approach involves blocking two specific proteins to improve NK cells' ability to attack cancer cells. In preclinical studies, these enhanced NK cells successfully killed human cancer cells from aggressive types such as leukemia, glioblastoma, kidney cancer, and triple-negative breast cancer. The treatment also significantly slowed tumor growth in animal models. Unlike many modern cancer immunotherapies that rely on permanent genetic modifications, this method uses small-molecule drugs to temporarily boost NK cell activity, offering a potentially safer and more controllable form of immunotherapy.

Parker Institute for Cancer Immunotherapy Showcases Research at ASCO 2026

Parker Institute for Cancer Immunotherapy Showcases Research at ASCO 2026

The Parker Institute for Cancer Immunotherapy (PICI) is set to have a significant presence at the American Society of Clinical Oncology (ASCO) Annual Meeting from May 29 to June 2, 2026. PICI will contribute to over 50 oral sessions, posters, and publications, highlighting its extensive work in cancer immunotherapy. The institute's research spans various cancers, including glioblastoma, melanoma, prostate, breast, lung, and urothelial cancers. Notably, PICI will present new data from its RADIOHEAD pan-cancer cohort, focusing on multimodal immunoprofiling to predict immunotherapy responses and toxicity. Additionally, PICI will announce the first recipient of the Conquer Cancer PICI Endowed Young Investigator Award, recognizing an outstanding early-career clinical oncology investigator.